Common Contracts

PURCHASE AND SALE AGREEMENT dated as of October 8, 2024 by and among SCILEX HOLDING COMPANY, SCILEX PHARMACEUTICALS INC., as the Seller Parties and efshar hataya ltd, ORAMED PHARMACEUTICALS INC., and 3i, LP as the Purchasers

Purchase and Sale Agreement • October 8th, 2024 • Oramed Pharmaceuticals Inc. • Pharmaceutical preparations • New York

• Contract Type
  Purchase and Sale Agreement
• Filed
  October 8th, 2024
• Company
  Oramed Pharmaceuticals Inc.
• Industry
  Pharmaceutical preparations
• Jurisdiction
  New York

This PURCHASE AND SALE AGREEMENT (this “Agreement”), dated as of October 8, 2024, is by and between SCILEX PHARMACEUTICALS INC., a Delaware corporation (the “Seller”), SCILEX HOLDING COMPANY, a Delaware corporation (the “Seller Parent”, and together with the Seller, the “Seller Parties”), Efshar Hataya Ltd, a Marshall Islands corporation (“Murchinson”), and Oramed Pharmaceuticals Inc., a Delaware corporation (“Oramed”) and 3I, LP, a Delaware limited partnership (“3i”, and, together with Murchinson and Oramed, collectively, the “Purchasers” and each, individually, a “Purchaser”).

PURCHASE AND SALE AGREEMENT dated as of October 8, 2024 by and among SCILEX HOLDING COMPANY, SCILEX PHARMACEUTICALS INC., as the Seller Parties and EFSHAR HATAYA LTD, ORAMED PHARMACEUTICALS INC., and 3i, LP as the Purchasers

Purchase and Sale Agreement • October 8th, 2024 • Scilex Holding Co • Biological products, (no disgnostic substances) • New York

• Contract Type
  Purchase and Sale Agreement
• Filed
  October 8th, 2024
• Company
  Scilex Holding Co
• Industry
  Biological products, (no disgnostic substances)
• Jurisdiction
  New York

This PURCHASE AND SALE AGREEMENT (this “Agreement”), dated as of October 8, 2024, is by and between SCILEX PHARMACEUTICALS INC., a Delaware corporation (the “Seller”), SCILEX HOLDING COMPANY, a Delaware corporation (the “Seller Parent”, and together with the Seller, the “Seller Parties”), EFSHAR HATAYA LTD, a Marshall Islands corporation (“Murchinson”), and ORAMED PHARMACEUTICALS INC., a Delaware corporation (“Oramed”) and 3I, LP, a Delaware limited partnership (“3i”, and, together with Murchinson and Oramed, collectively, the “Purchasers” and each, individually, a “Purchaser”).